Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults

Vaccine

Volumn 32, Issue 43, 2014, Pages 5657-5661

  Giacomet, Vania ^a   Penagini, Francesca ^a   Trabattoni, Daria ^a   Viganò, Alessandra ^a   Rainone, Veronica ^a   Bernazzani, Giada ^a   Bonardi, Claudia Maria ^a   Clerici, Mario ^a,c   Bedogni, Giorgio ^b   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c Liver Research Center   (Italy)

Author keywords

HIV; HPV; Quadrivalent HPV vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MALAISE; MALE; OUTCOME ASSESSMENT; PAIN; SEROCONVERSION; SKIN INDURATION; VACCINATION; BLOOD; CONDYLOMATA ACUMINATA; CONTROLLED CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CONDYLOMATA ACUMINATA; FEMALE; HIV INFECTIONS; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84908419622     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.011     Document Type: Article

References (19)

1. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J.T., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
2. Bhatia N., Lynde C., Vender R., Bourcier M. Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus. J Cutan Med Surg 2013, 17(Suppl. 2):S47-S54.
3. Veldhuijzen N.J., Braunstein S.L., Vyankandondera J., Ingabire C., Ntirushwa J., Kestelyn E. The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda. BMC Infect Dis 2011, 11:333.
4. Camargo M., Soto-De Leon S., Munoz M., Sanchez R., Pena-Herrera D., Pineda-Pena A.C., et al. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer 2014, 14:451.
5. Carter J.R., Ding Z., Rose Br HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 2011, 51(2):103-108.
6. Heard I., Cubie H.A., Mesher D., Sasieni P. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2013, 120:41-49. MACH-1 Study Group.
7. Hernandez A.L., Efird J.T., Holly E.A., Berry J.M., Jay N., Palefsky J.M. Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSM. AIDS 2014, 28:1341-1349.
8. van Rijn V.M., Mooij S.H., Mollers M., Snijders P.J.F., Speksnijder A.G., King A.J., et al. Anal penile, and oral high- risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLOS ONE 2014, 9(3):e99208.
9. Kreuter A., Wieland U. Human papillomavirus diseases in HIV-infected men who have sex with men. Curr Opin Infect Dis 2009, 22:109-114.
10. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2007, 56(RR02):1-24.
11. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR 2010, 58(20):630-632.
12. Dunne E.F., Markowitz L.E., Chesson H., Curtis C.R., Saraiya M., Gee J., et al. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - advisory committee on immunization practices (ACIP). MMWR 2011, 60(50):1705-1708.
13. Kojic E.M., Kang M., Cespedes E.S., Umbleja T., Godfrei C., Allen R.T., et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014, 59:127-135.
14. Wilkin T., Lee J.Y., Lensing S.Y., Stier E.A., Goldstone S.E., Berry J.M., et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010, 202(8):1246-1253.
15. Levin M.J., Moscicki A.B., Song L.Y., Fenton T., Meyer W.A., Read J.S., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010, 55(2):197-204.
16. Kahn J.A., Xu J., Kapogiannis B.G., Rudy B., Gonin R., Liu N., et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013, 57:735-744.
17. Macartney K., Chiu C., Georgousakis M., Brotherton J.M.L. Safety of human papillomavirus vaccines: a review. Drug Saf 2013, 36:393-412.
18. Hardin J.W., Hilbe J.M. Generalized estimating equations 2013, CRC Press.
19. Block S.L., Brown D.L., Chatterjee A., Gold M.A., Sings H.L., Meibohm A., et al. Clinical trial and post licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus like particle vaccine. Pediatr Infect Dis J 2010, 29:95-101.